A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.

Minna LehtisaloSuvi TaskinenE Katriina TarkiainenMikko NeuvonenJenni ViinamäkiMaria Paile-HyvärinenTuomas Olavi LiliusTuija TapaninenJanne T Backman Aleksi Tornio Mikko Niemi

Published in: British journal of clinical pharmacology (2022)

These data suggest roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Poor SLCO1B1 or ABCG2 function genotypes may increase the risk of rosuvastatin-induced myotoxicity. Reduced doses of rosuvastatin are advisable for patients with these genotypes.

Keyphrases

electronic health record
cancer stem cells
high glucose
big data
oxidative stress
deep learning